Catherine Tamalet1, Philippe Halfon2, Laurence Le Retraite3, Anne Grob4, François Xavier Leandri5, Patrice Heid5, Helene Sancho-Garnier6, Lucien Piana5. 1. Fondation Institut Hospitalo-Universitaire Méditerranée Infection, Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Centre Hospitalo-Universitaire Timone, 264 rue Saint-Pierre 13385, Marseille Cedex 05, France. Electronic address: ctamalet@ap-hm.fr. 2. Laboratoire Alphabio, Hôpital Européen, 6 Rue Désirée Clary, 13003 Marseille, France. Electronic address: Philippe.halfon@alphabio.fr. 3. Association pour la recherche et le dépistage des cancers du sein, du col de l'utérus et des cancers colorectaux (Arcades), Parc MÛre, Bâtiment A, 16 Bd des Aciéries, CS 90006, 13395 Marseille Cedex 10, France. Electronic address: laurence.leretraite@arcades-depistages.com. 4. Laboratoire départemental d'analyses, Technopôle de Château, Gombert Marseille, France. Electronic address: anne.grob@cg13.fr. 5. Association pour la recherche et le dépistage des cancers du sein, du col de l'utérus et des cancers colorectaux (Arcades), Parc MÛre, Bâtiment A, 16 Bd des Aciéries, CS 90006, 13395 Marseille Cedex 10, France. Electronic address: secretariat.col@arcades-depistages.com. 6. Fondation JDB Prevention Cancer, Fontaine les Briis 91640, France. Electronic address: Helene.Sancho-Garnier@icm.unicancer.fr.
Abstract
BACKGROUND: HPV vaginal self-sampling can be an alternative for women refusing cytological screening. OBJECTIVES: To describe HR-HPV types in 35-69 years old women from low socioeconomic groups not attending regular cytological screening in Marseille, France. STUDY DESIGN: A cervical screening campaign using HR-HPV self-sampling including 22,702 women aged 35-69 years living in low socioeconomic districts of Marseille was organized. A cytological and/or histological follow-up was undertaken for a subset of women harboring HR-HPV types. Abbott RealTime High Risk HPV test was used for screening, while INNO-LiPA HPV Genotyping Extra assay was used for genotyping. RESULTS: 4245 self-samplings were performed (participation rate, 18.7%) out of which 609 (14.3%) were HR-HPV+ by the screening test including 114HPV 16 (18.7%), 41HPV 18 (6.7%), 454HR-HPVnon-16/18 (75.4%). A sample of 260 out of the 454HR-HPVnon-16/18 were genotyped by INNO-LiPA which revealed HPV52 (35%), 66 (22.6%), 51 (19.6%), 31 (15.7%), 39 (13%), 56 (10.4%), and 53, 35, 59, 33, 58, 82, 45, 68, 73 (<10% each). At month 12, a 2nd self-collection kit was sent to 274 of 609HR-HPV+ women who did not have a Pap-test previously performed on them. Of these 274 women, 130 provided a sample for HPV testing; one was uninterpretable, 56 were HPV negative, and 73 were HR-HPV+ (10HPV16+, 3HPV18+, 60HR-HPVnon-16/18+). Of the 345 women with cytological and/or histological follow-up 19 (5.5%) had ≥CIN2 lesions, (11 were HPV16+ and 8 were HR-HPVnon-16/18). CONCLUSION: This study illustrates the potential efficacy of self-sampling as a cancer screening strategy for socioeconomically deprived women who do not participate in regular Pap screening programs.
BACKGROUND: HPV vaginal self-sampling can be an alternative for women refusing cytological screening. OBJECTIVES: To describe HR-HPV types in 35-69 years old women from low socioeconomic groups not attending regular cytological screening in Marseille, France. STUDY DESIGN: A cervical screening campaign using HR-HPV self-sampling including 22,702 women aged 35-69 years living in low socioeconomic districts of Marseille was organized. A cytological and/or histological follow-up was undertaken for a subset of women harboring HR-HPV types. Abbott RealTime High Risk HPV test was used for screening, while INNO-LiPA HPV Genotyping Extra assay was used for genotyping. RESULTS: 4245 self-samplings were performed (participation rate, 18.7%) out of which 609 (14.3%) were HR-HPV+ by the screening test including 114HPV 16 (18.7%), 41HPV 18 (6.7%), 454HR-HPVnon-16/18 (75.4%). A sample of 260 out of the 454HR-HPVnon-16/18 were genotyped by INNO-LiPA which revealed HPV52 (35%), 66 (22.6%), 51 (19.6%), 31 (15.7%), 39 (13%), 56 (10.4%), and 53, 35, 59, 33, 58, 82, 45, 68, 73 (<10% each). At month 12, a 2nd self-collection kit was sent to 274 of 609HR-HPV+ women who did not have a Pap-test previously performed on them. Of these 274 women, 130 provided a sample for HPV testing; one was uninterpretable, 56 were HPV negative, and 73 were HR-HPV+ (10HPV16+, 3HPV18+, 60HR-HPVnon-16/18+). Of the 345 women with cytological and/or histological follow-up 19 (5.5%) had ≥CIN2 lesions, (11 were HPV16+ and 8 were HR-HPVnon-16/18). CONCLUSION: This study illustrates the potential efficacy of self-sampling as a cancer screening strategy for socioeconomically deprived women who do not participate in regular Pap screening programs.
Authors: Annarosa Del Mistro; Helena Frayle; Martina Rizzi; Gianpiero Fantin; Antonio Ferro; Paolo Matteo Angeletti; Paolo Giorgi Rossi; Emma Altobelli Journal: PLoS One Date: 2017-03-06 Impact factor: 3.240